NEW YORK, Aug. 10, 2016 /PRNewswire/ -- The IVD and laboratory industry met in Philadelphia for the American Association for Clinical Chemistry last week in Philadelphia, but not everyone interested could make it. To accommodate interested IVD market-watchers who could not attend, healthcare market research firm Kalorama Information has released a White Paper tying together some of the top events, noticeable trends and new diagnostic science evident at the meeting. These included a focus on automated solutions, musings about new strategies, a slew of new products and new developments in the science of testing. The white paper, What You May Have Missed at AACC 2016 is available at http://content.marketresearch.com/white-paper-aacc2016. Kalorama Information routinely reports on the in vitro diagnostics industry and is soon to publish the tenth edition of its comprehensive report on the industry.
This year's meeting was particularly important as the AACC said that its attendance had reached 20,000 and was 14% up from the previous year's meeting. It featured national news publicity and talk of industry disruption. There was also a focus on automated solutions, dealing with Zika and new scientific discoveries.
"If you did not get a chance to come to Philadelphia this year, or if you were there but looking for a broad perspective on the meeting, our analysts did attend and we share their insights," said Bruce Carlson, Publisher of Kalorama Information. "We also attended press conferences and held meetings with vendors, learning about their opportunities, their strategies and their concerns in the marketplace. The White Paper sums up these findings."
The meeting has grown and is so vast that even attendees might benefit from a broader perspective on the meeting, according to Kalorama. There are hundreds of exhibitors selling to lab professionals, and often companies were giving press conferences at the same time. Nonetheless, Kalorama's team uncovered useful highlights. That Roche was presenting the new CLIA-waiver on its cobas Liat for flu A/B, and RSV, and aiming at new venues like retail clinics, while bioMerieux aiming to assist busy microbiology labs with an automated solution, that Siemens Healthineers launched a new improved-workflow analyzer, and Ortho Clinical Diagnostics promoted its strength in immunohematology, while Bio-Rad aimed at simplifying quality control in molecular HAI testing. There was science discussed at the meeting – from concern over cannabis DUI testing to new applications for liquid biopsy. As well as several Zika tests, as the industry confronted the scourge.
"Theranos brought attention to the AACC meeting and quite likely the news media focused on diagnostic testing for a few days in a way they need to do more," said Carlson. "But it would be a mistake to say the one session dominated the meeting. The big takeaway from AACC 2016 was about productivity improvements in existing technology that are, in reality, just as game-changing as the disruptive new technologies suggested at the first session. Our White Paper covers those developments."
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/kalorama-couldnt-make-it-to-aacc-2016--new-white-paper-sums-up-ivd-and-lab-trends-evident-at-meeting-300311801.html
SOURCE Kalorama Information